Typhoid vaccine

Last updated

Typhoid vaccine
Typhim.jpg
Vaccine description
Target Typhoid
Clinical data
Trade names Typhim Vi, Vivotif
AHFS/Drugs.com Monograph
MedlinePlus a607028
Pregnancy
category
  • AU:B2
ATC code
Legal status
Legal status
Identifiers
ChemSpider
  • none
UNII
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Typhoid vaccines are vaccines that prevent typhoid fever. [1] [2] [3] Several types are widely available: typhoid conjugate vaccine (TCV), Ty21a (a live oral vaccine) and Vi capsular polysaccharide vaccine (ViPS) (an injectable subunit vaccine). They are about 30 to 70% effective in the first two years, depending on the specific vaccine in question. The Vi-rEPA vaccine has been shown to be efficacious in children. [4]

Contents

The World Health Organization (WHO) recommends vaccinating all children in areas where the disease is common. [1] Otherwise they recommend vaccinating those at high risk. [1] Vaccination campaigns can also be used to control outbreaks of disease. [1] Depending on the vaccine, additional doses are recommended every three to seven years. [1] In the United States the vaccine is only recommended in those at high risk such as travelers to areas of the world where the disease is common. [5]

The vaccines available as of 2018 are very safe. [1] Minor side effects may occur at the site of injection. [1] The injectable vaccine is safe in people with HIV/AIDS and the oral vaccine can be used as long as symptoms are not present. [1] While it has not been studied during pregnancy, the non-live vaccines are believed to be safe while the live vaccine is not recommended. [1]

The first typhoid vaccines were developed in 1896 by Almroth Edward Wright, Richard Pfeiffer, and Wilhelm Kolle. [6] Due to side-effects newer formulations are recommended as of 2018. [1] It is on the World Health Organization's List of Essential Medicines. [7] [8]

Medical uses

Ty21a, the Vi capsular polysaccharide vaccine, and Vi-rEPA are effective in reducing typhoid fever with low rates of adverse effects. [4] Newer vaccines such as Vi-TT (PedaTyph) are awaiting[ when? ] field trials to demonstrate efficacy against natural exposure. [4]

The oral Ty21a vaccine prevents around one-half of typhoid cases in the first three years after vaccination. The injectable Vi polysaccharide vaccine prevented about two-thirds of typhoid cases in the first year and had a cumulative efficacy of 55% by the third year. The efficacy of these vaccines has only been demonstrated in children older than two years. [4] Vi-rEPA vaccine, a new conjugate form of the injectable Vi vaccine, may be more effective and prevents the disease in many children under the age of five years. [9] In a trial in 2-to-5-year-old children in Vietnam, the vaccine had more than 90 percent efficacy in the first year and protection lasted at least four years. [10]

Schedule

Depending on the formulation it can be given starting at the age of two (ViPS), six (Ty21a), or six months (TCV). [1]

Types

Related Research Articles

<span class="mw-page-title-main">Typhoid fever</span> Disease caused by the bacteria Salmonella Typhi

Typhoid fever, also known as typhoid, is a disease caused by Salmonella serotype Typhi bacteria. Symptoms vary from mild to severe, and usually begin six to 30 days after exposure. Often there is a gradual onset of a high fever over several days. This is commonly accompanied by weakness, abdominal pain, constipation, headaches, and mild vomiting. Some people develop a skin rash with rose colored spots. In severe cases, people may experience confusion. Without treatment, symptoms may last weeks or months. Diarrhea may be severe, but is uncommon. Other people may carry it without being affected, but are still contagious. Typhoid fever is a type of enteric fever, along with paratyphoid fever. S. enterica Typhi is believed to infect and replicate only within humans.

<span class="mw-page-title-main">Conjugate vaccine</span> Type of vaccine

A conjugate vaccine is a type of subunit vaccine which combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

<span class="mw-page-title-main">Pneumococcal polysaccharide vaccine</span> Pneumonia vaccine

Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. It is given by intramuscular or subcutaneous injection.

The MMRV vaccine combines the attenuated virus MMR vaccine with the addition of the chickenpox vaccine or varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age.

<span class="mw-page-title-main">Pneumococcal conjugate vaccine</span> Vaccine against Strep pneumoniae

Pneumococcal conjugate vaccine is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children.

<span class="mw-page-title-main">Pneumococcal vaccine</span> Vaccine to prevent infection by the bacteria Stretococcus pneumoniae

Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. They are given by injection either into a muscle or just under the skin.

<span class="mw-page-title-main">Hepatitis A vaccine</span> Vaccine to prevent hepatitis A

Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle. The first hepatitis A vaccine was approved in Europe in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines.

<span class="mw-page-title-main">Hib vaccine</span> Haemophilus influenzae type B vaccine

The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis.

The rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.

John Bennett Robbins was a senior investigator at the National Institutes of Health (NIH), best known for his contribution to the development of the vaccine against bacterial meningitis Hib)) with his colleague Rachel Schneerson. He conducted research on the Bethesda, Maryland campus of the NIH from 1970 until his retirement at the age of 80 in 2012. During his tenure, he worked in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Food and Drug Administration’s biologics laboratories on location.

The Vi capsular polysaccharide vaccine is a typhoid vaccine recommended by the World Health Organization for the prevention of typhoid. The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine.

<span class="mw-page-title-main">Rabies vaccine</span> Vaccines to prevent rabies in humans and animals

The rabies vaccine is a vaccine used to prevent rabies. There are several rabies vaccines available that are both safe and effective. They can be used to prevent rabies before, and, for a period of time, after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.

<span class="mw-page-title-main">Ty21a</span> Typhoid vaccine

Ty21a is a live attenuated bacterial vaccine that protects against typhoid. First licensed in Europe in 1983 and in the United States in 1989, it is an orally administered, live-attenuated Ty2 strain of S. Typhi in which multiple genes, including the genes responsible for the production of Vi, have been deleted so as to render it harmless but nevertheless immunogenic. It is one of the three typhoid vaccines currently recommended by the World Health Organization.

NmVac4-A/C/Y/W-135 is the commercial name of the polysaccharide vaccine against the bacterium that causes meningococcal meningitis. The product, by JN-International Medical Corporation, is designed and formulated to be used in developing countries for protecting populations during meningitis disease epidemics.

<span class="mw-page-title-main">Cholera vaccine</span> Vaccine to prevent cholera

A cholera vaccine is a vaccine that is effective at preventing cholera. For the first six months after vaccination it provides about 85 percent protection, which decreases to 50 percent or 62 percent during the first year. After two years the level of protection decreases to less than 50 percent. When enough of the population is immunized, it may protect those who have not been immunized.

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

<span class="mw-page-title-main">Tetanus vaccine</span> Vaccines used to prevent tetanus

Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence.

Dengue vaccine is a vaccine used to prevent dengue fever in humans. Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.

Melita Alison Gordon is a gastroenterologist who works on invasive gut pathogens and tropical gastrointestinal disease. She leads the Malawi Liverpool Wellcome Trust Salmonella and Enterics Group. Gordon was awarded the British Society of Gastroenterology Sir Francis Avery Jones Research Medal in 2011.

<span class="mw-page-title-main">Vaccine ingredients</span> Ingredients used in a vaccine dose

A vaccine dose contains many ingredients very little of which is the active ingredient, the immunogen. A single dose may have merely nanograms of virus particles, or micrograms of bacterial polysaccharides. A vaccine injection, oral drops or nasal spray is mostly water. Other ingredients are added to boost the immune response, to ensure safety or help with storage, and a tiny amount of material is left-over from the manufacturing process. Very rarely, these materials can cause an allergic reaction in people who are very sensitive to them.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 World Health Organization (2018). "Typhoid vaccines: WHO position paper – March 2018". Weekly Epidemiological Record. 93 (13): 153–172. hdl:10665/272273.
  2. "Summary of the WHO Position Paper on Typhoid vaccines: WHO position paper – March 2018" (PDF). origin.who.int. 23 October 2019. Archived from the original (PDF) on 23 October 2019.
  3. World Health Organization (2019). "Typhoid vaccines: WHO position paper, March 2018 - Recommendations". Vaccine. 37 (2): 214–216. doi:10.1016/j.vaccine.2018.04.022. PMID   29661581. S2CID   4902671.
  4. 1 2 3 4 Milligan R, Paul M, Richardson M, Neuberger A (May 2018). "Vaccines for preventing typhoid fever". The Cochrane Database of Systematic Reviews. 2018 (5): CD001261. doi:10.1002/14651858.CD001261.pub4. PMC   6494485 . PMID   29851031.
  5. "Typhoid Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). October 2019. Archived from the original on 8 December 2015. Retrieved 15 December 2015.
  6. Flower DR (2008). Bioinformatics for Vaccinology. Chichester: John Wiley & Sons. pp. 40–41. ISBN   9780470699829. Archived from the original on 22 December 2015.
  7. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  9. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. (April 2001). "The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children". The New England Journal of Medicine. 344 (17): 1263–9. doi: 10.1056/nejm200104263441701 . PMID   11320385.{{cite journal}}: CS1 maint: overridden setting (link)
  10. Szu SC (November 2013). "Development of Vi conjugate - a new generation of typhoid vaccine". Expert Review of Vaccines. 12 (11): 1273–86. doi:10.1586/14760584.2013.845529. PMID   24156285. S2CID   23280555.
  11. "Typhim Vi". U.S. Food and Drug Administration (FDA). 22 July 2017. Retrieved 29 December 2019.
  12. "Vivotif". U.S. Food and Drug Administration (FDA). 1 February 2018. Retrieved 29 December 2019.
  13. "Typhoid vaccine prequalified". who.int. 3 January 2018. Archived from the original on 4 January 2018. Retrieved 9 December 2019.